Question Title

1. I am:

Epidemiology

Question Title

2. Which of the following do you consider to be the most problematic fungal pathogen at your institution?

Question Title

3. In your practice, how often do you encounter Candida isolates that exhibit resistance to azole therapy?

Question Title

4. At your institution, first-line treatment for a patient with neutropenic fever (>72 hours) and with a suspected Candida infection is:

Diagnostics

Question Title

5. A diagnostic test to differentiate among Candida species from blood culture is:

Question Title

6. At your institution, when an IFI is suspected, how much time typically passes before antifungal treatment is initiated?

Question Title

7. When invasive candidiasis is confirmed, how often do you request for susceptibility testing?

Prophylaxis

Question Title

8. How often do you utilize IDSA guidelines when selecting antifungal prophylaxis for at-risk patients?

Question Title

9. When selecting antifungal prophylaxis, I consider the local epidemiology when choosing the agent?

Question Title

10. The most common antifungal agent used for prophylaxis at your institution is:

Treatment

Question Title

11. At your institution, how often is combination antifungal therapy used for empiric treatment of invasive fungal infections?

Question Title

12. How often do you utilize IDSA guidelines when selecting treatment for candidiasis or aspergillosis?

Question Title

13. Which of the following present significant challenges to you when treating an IFI? (check all that apply)

T